Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to optimize dermal ...
Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal ...
Quoin Pharmaceuticals Ltd. has announced the filing of U.S. and International patent applications for new topical formulations of rapamycin aimed at treating rare diseases such as microcystic ...
Add Yahoo as a preferred source to see more of our stories on Google. When Portia Cina posted a video about prom on TikTok, she noticed people asked a lot of questions. She has the rare condition ...
Quoin Pharmaceuticals Ltd. has filed a U.S. patent application for new topical formulations aimed at treating several skin diseases, specifically Netherton Syndrome (NS) and Peeling Skin Syndrome. The ...
Steven Daniel Daveluy, MD, FAAD, discussed how artificial intelligence (AI) can leverage extensive patient data and guide dermatologists to improve early diagnosis and treatment of rare dermatological ...
Curious about the most rare disease in the world? Discover the top 10 ultra-rare diseases, their symptoms, causes.
ROOTSTOWN, Ohio--(BUSINESS WIRE)--BioMendics, a clinical-stage biopharmaceutical company focused on rare skin diseases, today announced the launch of the TAMES-02 clinical trial—a multicenter, ...
There is a promising new drug for the rare disease mastocytosis, which is associated with skin lesions, among other things.
Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results